Zachary A. Gurard-Levin, Ph.D. - Publications

2010 Chemistry University of Chicago, Chicago, IL 
chemical biology of cell adhesion

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Gurard-Levin ZA, Liu C, Jekle A, Jaisinghani R, Ren S, Vandyck K, Jochmans D, Leyssen P, Neyts J, Blatt LM, Beigelman L, Symons JA, Raboisson P, Scholle MD, Deval J. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Research. 104924. PMID 32896566 DOI: 10.1016/j.antiviral.2020.104924  0.68
2019 Buker SM, Gurard-Levin ZA, Wheeler BD, Scholle MD, Case AW, Hirsch JL, Ribich S, Copeland RA, Boriack-Sjodin PA. A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity. Slas Discovery : Advancing Life Sciences R & D. 2472555219878408. PMID 31585521 DOI: 10.1177/2472555219878408  0.68
2016 Gurard-Levin ZA, Wilson LO, Pancaldi V, Postel-Vinay S, Sousa FG, Reyes C, Marangoni E, Gentien D, Valencia A, Pommier Y, Cottu P, Almouzni G. Chromatin regulators as a guide for cancer treatment choice. Molecular Cancer Therapeutics. PMID 27196757 DOI: 10.1158/1535-7163.MCT-15-1008  1
2015 Bonneau C, Gurard-Levin ZA, Andre F, Pusztai L, Rouzier R. Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Research. 35: 5179-84. PMID 26408675  1
2014 Gurard-Levin ZA. Epi-drugs, a new hope for cancer treatment | Les épidrogues, un nouvel espoir pour le traitement du cancer Biofutur. 48-50.  0.4
2013 Abascal F, Corpet A, Gurard-Levin ZA, Juan D, Ochsenbein F, Rico D, Valencia A, Almouzni G. Subfunctionalization via adaptive evolution influenced by genomic context: the case of histone chaperones ASF1a and ASF1b. Molecular Biology and Evolution. 30: 1853-66. PMID 23645555 DOI: 10.1093/molbev/mst086  1
2011 Gurard-Levin ZA, Scholle MD, Eisenberg AH, Mrksich M. High-throughput screening of small molecule libraries using SAMDI mass spectrometry. Acs Combinatorial Science. 13: 347-50. PMID 21639106 DOI: 10.1021/co2000373  1
2011 Evans AS, Cohen AD, Gurard-Levin ZA, Kebede N, Celius TC, Miceli AP, Toscano JP. Photogeneration and reactivity of acyl nitroso compounds Canadian Journal of Chemistry. 89: 130-138. DOI: 10.1139/V10-101  1
2010 Gurard-Levin ZA, Kilian KA, Kim J, Bähr K, Mrksich M. Peptide arrays identify isoform-selective substrates for profiling endogenous lysine deacetylase activity Acs Chemical Biology. 5: 863-873. PMID 20849068 DOI: 10.1021/cb100088g  1
2010 Mwakwari SC, Guerrant W, Patil V, Khan SI, Tekwani BL, Gurard-Levin ZA, Mrksich M, Oyelere AK. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton Journal of Medicinal Chemistry. 53: 6100-6111. PMID 20669972 DOI: 10.1021/jm100507q  1
2009 Gurard-Levin ZA, Kim J, Mrksich M. Combining mass spectrometry and peptide arrays to profile the specificities of histone deacetylases Chembiochem. 10: 2159-2161. PMID 19688789 DOI: 10.1002/cbic.200900417  1
2008 Gurard-Levin ZA, Mrksich M. Combining self-assembled monolayers and mass spectrometry for applications in biochips Annual Review of Analytical Chemistry. 1: 767-800. PMID 20636097 DOI: 10.1146/annurev.anchem.1.031207.112903  1
2008 Gurard-Levin ZA, Mrksich M. The activity of HDAC8 depends on local and distal sequences of its peptide substrates Biochemistry. 47: 6242-6250. PMID 18470998 DOI: 10.1021/bi800053v  1
2004 Bradshaw EM, Sanford DG, Luo X, Sudmeier JL, Gurard-Levin ZA, Bullock PA, Bachovchin WW. T antigen origin-binding domain of simian virus 40: determinants of specific DNA binding. Biochemistry. 43: 6928-36. PMID 15170330 DOI: 10.1021/bi030228+  1
2003 Gurard-Levin ZA. Les épidrogues, un nouvel espoir pour le traitement du cancer Journal of the Institution of Engineers (India): Aerospace Engineering Journal. 84: 48-50.  0.36
Show low-probability matches.